ATE111443T1 - Auf hydroxaminsäure basierte kollagenaseinhibitoren. - Google Patents

Auf hydroxaminsäure basierte kollagenaseinhibitoren.

Info

Publication number
ATE111443T1
ATE111443T1 AT90911398T AT90911398T ATE111443T1 AT E111443 T1 ATE111443 T1 AT E111443T1 AT 90911398 T AT90911398 T AT 90911398T AT 90911398 T AT90911398 T AT 90911398T AT E111443 T1 ATE111443 T1 AT E111443T1
Authority
AT
Austria
Prior art keywords
hydroxamic acid
inhibitors based
collagenase inhibitors
disease
involving
Prior art date
Application number
AT90911398T
Other languages
English (en)
Inventor
Colin Campion
Alan Hornsby Davidson
Jonathan Philip Dickens
Michael John Crimmin
Original Assignee
British Bio Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Bio Technology filed Critical British Bio Technology
Application granted granted Critical
Publication of ATE111443T1 publication Critical patent/ATE111443T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT90911398T 1989-08-24 1990-07-20 Auf hydroxaminsäure basierte kollagenaseinhibitoren. ATE111443T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898919251A GB8919251D0 (en) 1989-08-24 1989-08-24 Compounds

Publications (1)

Publication Number Publication Date
ATE111443T1 true ATE111443T1 (de) 1994-09-15

Family

ID=10662057

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90911398T ATE111443T1 (de) 1989-08-24 1990-07-20 Auf hydroxaminsäure basierte kollagenaseinhibitoren.

Country Status (16)

Country Link
US (2) US5453438A (de)
EP (1) EP0489032B1 (de)
JP (1) JP2871849B2 (de)
KR (1) KR927003624A (de)
AT (1) ATE111443T1 (de)
AU (1) AU639706B2 (de)
CA (1) CA2064786A1 (de)
DE (1) DE69012575T2 (de)
DK (1) DK0489032T3 (de)
ES (1) ES2063975T3 (de)
FI (1) FI920771A0 (de)
GB (1) GB8919251D0 (de)
NO (1) NO920702L (de)
NZ (1) NZ235050A (de)
TW (1) TW202456B (de)
WO (1) WO1991002716A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
EP0520573A1 (de) * 1991-06-27 1992-12-30 Glaxo Inc. Derivate von cyclischen Imiden
DE69309047T2 (de) * 1992-04-07 1997-09-11 British Biotech Pharm Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5326760A (en) * 1992-06-29 1994-07-05 Glaxo, Inc. Aminobutanoic acid compounds having metalloprotease inhibiting properties
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
DE69412469T2 (de) * 1993-03-16 1999-02-04 British Biotech Pharm Hydroxamsaeurederivate als metalloproteinase inhibitoren
ATE182137T1 (de) * 1993-04-27 1999-07-15 Celltech Therapeutics Ltd Peptidylderivate als inhibitoren von metalloproteinase
GB9308695D0 (en) * 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
ES2075798B1 (es) * 1993-08-18 1996-03-01 British Bio Technology Derivados de aminoacidos naturales como inhibidores de metaloproteinasas, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y el uso de dichos compuestos en medicina.
ES2075797B1 (es) * 1993-08-18 1996-05-16 British Bio Technology Derivados de acidos hidroxamicos terapeuticamente activos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y el uso de dichos compuestos en medicina.
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
KR100418808B1 (ko) * 1994-01-20 2004-07-23 브리티쉬 바이오테크 파마슈티칼스 리미티드 금속단백질분해효소억제제
GB9501737D0 (en) * 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
US5840698A (en) * 1994-10-27 1998-11-24 Affymax Technologies N.V. Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use
US5831004A (en) 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5639746A (en) * 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
US5919940A (en) * 1995-01-20 1999-07-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
CZ292617B6 (cs) 1995-11-23 2003-11-12 British Biotech Pharmaceuticals Limited Inhibitory metaloproteinázy a farmaceutický prostředek
BR9713186A (pt) * 1996-08-28 1999-11-03 Procter & Gamble Inibidores de metaloprotease 1,3-diheterocìclicos
WO1998008825A1 (en) * 1996-08-28 1998-03-05 The Procter & Gamble Company 1,4-heterocyclic metalloprotease inhibitors
BR9712085A (pt) 1996-08-28 2000-10-24 Procter & Gamble Inibidores de metaloprotease heterocìclicos
PL331920A1 (en) * 1996-08-28 1999-08-16 Procter & Gamble Spirocyclic inhibitors of metaloproteases
CA2264254C (en) * 1996-08-28 2003-03-11 Yetunde Olabisi Taiwo Phosphinic acid amides as matrix metalloprotease inhibitors
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
CA2265666C (en) * 1996-09-10 2008-01-15 British Biotech Pharmaceuticals Limited Cytostatic hydroxamic acid derivatives
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
KR100352316B1 (ko) 1997-07-31 2002-09-12 더 프록터 앤드 갬블 캄파니 메탈로프로테아제억제제로서사용되는술포닐아미노치환히드록삼산유도체
GB9810464D0 (en) * 1998-05-16 1998-07-15 British Biotech Pharm Hydroxamic acid derivatives
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
KR20010102486A (ko) 1999-03-03 2001-11-15 데이비드 엠 모이어 알케닐- 및 알키닐-함유 메탈로프로테아제 저해제
EP1202968A2 (de) 1999-08-10 2002-05-08 British Biotech Pharmaceuticals Limited Antibakterielle mittel
GB9929527D0 (en) * 1999-12-14 2000-02-09 Smithkline Beecham Plc Novel compounds
US6797820B2 (en) * 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
JP4314340B2 (ja) 2001-06-15 2009-08-12 ヴィキュロン ファーマシューティカルズ インコーポレイテッド ピロリジン二環性化合物
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105789A (en) * 1976-05-10 1978-08-08 E. R. Squibb & Sons, Inc. Carboxyalkylacylamino acids
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4499079A (en) * 1982-11-18 1985-02-12 E. R. Squibb & Sons, Inc. Carboxy and substituted carboxy alkanoyl and cycloalkanoyl peptides
US4496540A (en) * 1982-12-30 1985-01-29 Biomeasure, Inc. Therapeutic compounds
JPS6115840A (ja) * 1984-07-03 1986-01-23 Microbial Chem Res Found 免疫賦活剤
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes

Also Published As

Publication number Publication date
US5910609A (en) 1999-06-08
KR927003624A (ko) 1992-12-18
DK0489032T3 (da) 1995-01-30
EP0489032A1 (de) 1992-06-10
NZ235050A (en) 1991-12-23
CA2064786A1 (en) 1991-02-25
JP2871849B2 (ja) 1999-03-17
FI920771A0 (fi) 1992-02-21
WO1991002716A2 (en) 1991-03-07
DE69012575D1 (de) 1994-10-20
US5453438A (en) 1995-09-26
JPH05501864A (ja) 1993-04-08
NO920702L (no) 1992-04-23
ES2063975T3 (es) 1995-01-16
TW202456B (de) 1993-03-21
AU6045490A (en) 1991-04-03
NO920702D0 (no) 1992-02-21
AU639706B2 (en) 1993-08-05
DE69012575T2 (de) 1995-03-30
GB8919251D0 (en) 1989-10-04
EP0489032B1 (de) 1994-09-14
WO1991002716A3 (en) 1991-06-27

Similar Documents

Publication Publication Date Title
ATE111443T1 (de) Auf hydroxaminsäure basierte kollagenaseinhibitoren.
DE69734661D1 (de) Foerderung der wundheilung durch chemisch modifizierte tetracycline
ES2063334T3 (es) Inhibidores de la colagenasa basados en el acido hidroxamico.
DE50002293D1 (de) Verwendung von csf-1-inhibitoren
DK0766665T3 (da) Metalloproteinaseinhibitorer
NO911962D0 (no) Hydroksaminsyrebaserte kollagenaseinhibitorer.
DK1030836T3 (da) Hydroxam- og carboxylsyrederivater der har MMP- og TNF-inhiberende aktivitet
CY1105501T1 (el) Συνδυασμοι φαρμακων (π.χ. chlorpromazine και pentamidine) για την αντιμετωπιση νεοπλαστικων διαταραχων
PT696205E (pt) Utilizacao de linhas celulares fetais nauro-derivadas para terapia de transplantacao
EA200100721A1 (ru) Производное габапентина для предупреждения и лечения висцеральной боли
DK0850215T3 (da) N-(aroyl)glycinhydroxamsyrederivater og beslægtede forbindelser
EA199900542A1 (ru) Соединения сульфоновой кислоты или сульфониламино-n-(гетероаралкил)-азагетероциклиламида
EP0832100A4 (de) Neuartige metalloprotease-inhibitoren, diese enthaltende pharmazeutische zusammensetzungen und anwendungsverfahren
EA199700380A1 (ru) Бициклические ароматические соединения, фармацевтическая и косметическая композиции на их основе и применение косметической композиции
ES2041705T3 (es) Procedimiento para la preparacion de 1-(4-hidroxi-3,5-di-terc-butil-benzoil)-homopiperazina y sus derivados.
DE69419954T2 (de) Arzneimittel zur Behandlung von Hauterkrankungen
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
SE9303612D0 (sv) New use
DE69428797D1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
DE69828638D1 (de) Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität
RU94014833A (ru) Средство для лечения дегенеративных заболеваний суставов и околосуставных тканей
SE9903610D0 (sv) Novel compounds II
CO4780024A1 (es) Nuevos derivados del acido hidroxamico utiles para el tratamiento de enfermedades relacionadas con la degradacion del tejido conectivo
NO20082302L (no) Anvendelse av et pleuromutilinderivat innen vetrinaermedisin samt fremgangsmate for fremstilling av et medikament omfattende forbindelsen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee